Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395082 · ClinicalTrials.gov registry record
ACAM2000® Myopericarditis Registry
A clinical trial, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- 24
- Enrollment target
NCT01395082: Completed study, sponsored by Emergent BioSolutions.
NCT01395082 is a clinical trial that has completed, run by Emergent BioSolutions. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01395082 has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions. Primary Objective: \- To document the natural history of confirmed, probable, suspected, and subclinical myocarditis and pericarditis (myopericarditis) following ACAM2000® vaccination. Other Pre-defined Objective: \- To look for potential predictive factors for the prognosis of myopericarditis following ACAM2000® vaccination.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-04 |
| Est. Completion | 2019-02-04 |
What the finished NCT01395082 record still lists
NCT01395082 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01395082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01395082 about?
NCT01395082 is a clinical study titled "ACAM2000® Myopericarditis Registry". The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions. Primary Objective: \- To document the natural history of confirmed, probable, suspected, and subclinical myocarditis and perica...
What is the current status of trial NCT01395082?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-04. Estimated completion is 2019-02-04.
Who is sponsoring clinical trial NCT01395082?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia